CanBas Co., Ltd. (TYO:4575)

Japan flag Japan · Delayed Price · Currency is JPY
678.00
-14.00 (-2.02%)
May 12, 2026, 3:30 PM JST
Market Cap12.96B -21.2%
Revenue (ttm)n/a
Net Income-1.25B
EPS-63.94
Shares Out19.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume139,300
Average Volume121,825
Open690.00
Previous Close692.00
Day's Range676.00 - 708.00
52-Week Range655.00 - 1,558.00
Beta-0.85
RSI37.67
Earnings DateMay 14, 2026

About CanBas

CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 14
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4575
Full Company Profile

Financial Performance

Financial Statements